HK1092841A1 - Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes - Google Patents

Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes

Info

Publication number
HK1092841A1
HK1092841A1 HK06113457.3A HK06113457A HK1092841A1 HK 1092841 A1 HK1092841 A1 HK 1092841A1 HK 06113457 A HK06113457 A HK 06113457A HK 1092841 A1 HK1092841 A1 HK 1092841A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
diagnosing
kits
reagents
compositions
Prior art date
Application number
HK06113457.3A
Other languages
English (en)
Inventor
Liat Mintz
Original Assignee
Liat Mintz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liat Mintz filed Critical Liat Mintz
Publication of HK1092841A1 publication Critical patent/HK1092841A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK06113457.3A 2003-09-11 2006-12-07 Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes HK1092841A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/659,782 US7176292B2 (en) 2003-09-11 2003-09-11 Ghrelin variant protein
PCT/US2004/029230 WO2005026392A2 (en) 2003-09-11 2004-09-09 Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes

Publications (1)

Publication Number Publication Date
HK1092841A1 true HK1092841A1 (en) 2007-02-16

Family

ID=34273528

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06113457.3A HK1092841A1 (en) 2003-09-11 2006-12-07 Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes

Country Status (15)

Country Link
US (2) US7176292B2 (xx)
EP (1) EP1664346B1 (xx)
JP (2) JP2007504825A (xx)
KR (1) KR101081040B1 (xx)
CN (1) CN101023184A (xx)
AT (1) ATE480641T1 (xx)
AU (2) AU2004273053B2 (xx)
BR (1) BRPI0414365A (xx)
CA (1) CA2538514C (xx)
DE (1) DE602004029061D1 (xx)
HK (1) HK1092841A1 (xx)
IL (2) IL174195A (xx)
NZ (1) NZ546488A (xx)
RU (1) RU2420583C2 (xx)
WO (1) WO2005026392A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512971B2 (en) * 2002-12-10 2013-08-20 Echelon Biosciences, Inc. Compounds and methods of use thereof for assaying lysophospholipase D activity
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
EP1747264B1 (de) 2004-05-21 2012-09-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multizelluläre gewebe- und organkultursysteme
WO2005119525A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. 11βHSD1 CRYSTAL STRUCTURES FOR STRUCTURE BASED DRUG DESIGN
CA2626831A1 (en) * 2005-11-03 2007-05-18 Liat Mintz Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
AU2007227641B2 (en) 2006-03-13 2012-11-29 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
CA2647815C (en) 2006-03-28 2021-11-23 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
US8420365B2 (en) * 2007-10-08 2013-04-16 Bristol-Myers Squibb Company 11βhydroxysteroid dehydrogenase type 1
CA2715921A1 (en) * 2008-03-12 2009-09-17 Otago Innovation Limited Biomarkers
ES2372337B1 (es) * 2010-06-10 2013-01-18 Servicio Andaluz De Salud Variante de la ghrelina y sus usos.
US9657062B2 (en) 2012-02-03 2017-05-23 Zealand Pharma A/S Ghrelin analogues
CN102721819B (zh) * 2012-06-28 2014-08-13 广州瑞博奥生物科技有限公司 一种脂联素的竞争抑制性酶联免疫检测试剂盒及方法
WO2017018735A1 (ko) * 2015-07-24 2017-02-02 고려대학교 산학협력단 노화 판별용, 비만 판별용, 암 진단용 바이오마커 및 이를 이용한 진단키트

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291653B1 (en) 1997-03-24 2001-09-18 Zymogenetics, Inc. Antibodies to motilin homologs
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
ATE504001T1 (de) * 2001-08-17 2011-04-15 Fujirebio Kk Verfahren zur diagnose oder überwachung eines fehlers im zuckerstoffwechsel
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
WO2003055916A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Adiponectin fragments and conjugates
CN1886423A (zh) * 2002-01-18 2006-12-27 普罗特米克斯公司 脂联素的糖基同工型及其用途
US20060199761A1 (en) * 2002-01-31 2006-09-07 Japan Science And Technology Agency Insulin resistance improving agent
AU2007227641B2 (en) * 2006-03-13 2012-11-29 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation

Also Published As

Publication number Publication date
KR20060083208A (ko) 2006-07-20
EP1664346A2 (en) 2006-06-07
IL200120A0 (en) 2011-08-01
ATE480641T1 (de) 2010-09-15
RU2420583C2 (ru) 2011-06-10
US8088730B2 (en) 2012-01-03
RU2006111720A (ru) 2007-10-20
US20070086997A1 (en) 2007-04-19
IL174195A (en) 2012-08-30
BRPI0414365A (pt) 2006-11-14
WO2005026392A3 (en) 2005-08-11
JP2011182776A (ja) 2011-09-22
WO2005026392A2 (en) 2005-03-24
US20050059015A1 (en) 2005-03-17
CN101023184A (zh) 2007-08-22
CA2538514C (en) 2014-04-08
EP1664346B1 (en) 2010-09-08
NZ546488A (en) 2009-01-31
JP2007504825A (ja) 2007-03-08
CA2538514A1 (en) 2005-03-24
IL174195A0 (en) 2006-08-01
AU2010212460A1 (en) 2010-09-09
JP5314658B2 (ja) 2013-10-16
DE602004029061D1 (de) 2010-10-21
AU2004273053A1 (en) 2005-03-24
AU2004273053B2 (en) 2010-05-20
KR101081040B1 (ko) 2011-11-09
US7176292B2 (en) 2007-02-13

Similar Documents

Publication Publication Date Title
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ATE424560T1 (de) Marker für neuromyelitis optica
WO2004074455A3 (en) Fc REGION VARIANTS
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2005111212A3 (en) Biological bar code
TW200736611A (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
IL176674A0 (en) Fc region variants
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
EP2101772A4 (en) NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
WO2006091861A3 (en) Compositions and methods relating to cns lymphoma
WO2003038444A3 (en) Biomarkers of liver function
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2005056043A3 (en) Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
SG146459A1 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy
WO2007055996A3 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
EP1465911A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES, INSULIN RESISTANCE AND DYSLIPIDEMIA
WO2004009783A3 (en) Truncated rgr in t cell malignancy
NO20033401D0 (no) Kjemiske forbindelser
WO2005019454A8 (en) Novel rat calcium channel subunits and related probes, cell lines and methods

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150909